Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver and the third leading cause of death from cancer. However, currently there is no effective treatment for HCC. It is therefore urgent to develop novel therapeutic approaches for the treatment of HCC. Increasing evidence suggests that being able to modulate specific miRNAs may lead to the development of novel cancer therapies. Our studies (and others) indicate that a microRNA, miR-26a, represses proinflammatory cytokines, especially interleukin 6 (IL-6) and its downstream mediator, signal transducer and activator of transcription 3 (STAT3), suggesting a tumor suppressive role of miR-26a on HCC development. However, the role of miR-26a in HCC development in the setting consisting of both hepatocytes and Kupffer cells in appropriate HCC mouse models has not been determined. Furthermore, whether modulating miR-26a in hepatocytes and/or Kupffer cells can be an effective therapeutic approach for treating HCC has not been tested. The objective of this proposal is to investigate the molecular and cellular mechanisms by which miR-26a overexpression in hepatocytes and Kupffer cells inhibits HCC development. In addition, we have identified small molecules and developed siRNA/RNA in vivo targeted delivery technology that can increase miR-26a expression in the liver.
In Aim 1, we will determine the effect of overexpression of miR-26a in hepatocytes and in Kupffer cells on suppression of HCC development. We have generated hepatocyte-specific as well as Kupffer cell-specific miR-26a overexpression transgenic mice. We will use these unique transgenic mouse lines to define the cellular and molecular mechanisms by which miR-26a exerts its effect on HCC.
In Aim 2, we will determine the effect of small molecules on miR-26a induction and HCC suppression. We have also developed an innovative siRNA/RNA in vivo targeted delivery technology-- CpG-siRNA/RNA?that enables RNA in vivo delivery into Toll-like Receptor 9-positive Kupffer cells and inflammatory/malignant hepatocytes. CpG-Stat3 siRNA is moving towards clinical trials for glioma and lymphoma patients at City of Hope. We will assess the effect of both CpG-miR-26a and CpG-Stat3 siRNA on HCC development in hepatocytes or/and Kupffer cells in animal models. The proposed studies will not only provide mechanistic insights into pathways underlying HCC but also help to develop effective treatment strategies for HCC.

Public Health Relevance

We propose to extend our previous research to investigate the cellular and molecular mechanism by which a micro-RNA modulates the development of liver cancer. We will also determine the effect of small molecules and a novel targeted delivery technology to inhibit liver cancer development through inducing the expression of micro-RNA in the liver. The results may lay the foundation to develop new and effective treatment for liver cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA139158-06A1
Application #
9239522
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Alley, Michael C
Project Start
2011-01-25
Project End
2021-12-31
Budget Start
2017-01-16
Budget End
2017-12-31
Support Year
6
Fiscal Year
2017
Total Cost
$410,875
Indirect Cost
$173,375
Name
Beckman Research Institute/City of Hope
Department
Type
Research Institutes
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Ding, Lili; Sousa, Kyle M; Jin, Lihua et al. (2016) Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. Hepatology 64:760-73
Zhou, Hong; Zhang, Jiawei; Gu, Ying et al. (2016) Identification of a novel RNA giant nuclear body in cancer cells. Oncotarget 7:4724-34
Han, Weidong; Fu, Xianghui; Xie, Jiansheng et al. (2015) miR-26a enhances autophagy to protect against ethanol-induced acute liver injury. J Mol Med (Berl) 93:1045-55
Ding, Lili; Yang, Li; Wang, Zhengtao et al. (2015) Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B 5:135-44
Yu, Donna D; Sousa, Kyle M; Mattern, Daniell L et al. (2015) Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled bile acid receptor 1 (GP-BAR1, TGR5) agonists. Bioorg Med Chem 23:1613-28
Wang, Yan-Dong; Chen, Wei-Dong; Li, Cunbao et al. (2015) Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol 29:322-31
Huang, Xiong-fei; Zhao, Wei-yu; Huang, Wen-dong (2015) FXR and liver carcinogenesis. Acta Pharmacol Sin 36:37-43
Dong, Bingning; Lee, Ju-Seog; Park, Yun-Yong et al. (2015) Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun 6:5944
Gu, Ying; Zhou, Hong; Gan, Yichao et al. (2015) Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue. Oncotarget 6:15111-21
Fu, Xianghui; Dong, Bingning; Tian, Yan et al. (2015) MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J Clin Invest 125:2497-509

Showing the most recent 10 out of 34 publications